LAG-3 cyclic peptide inhibitor C25

LAG-3 cyclic peptide inhibitor C25 is a LAG-3 inhibitor. LAG-3 cyclic peptide inhibitor C25 has a high affinity with human LAG-3 protein with a Kd value of 0.66 μM. LAG-3 cyclic peptide inhibitor C25 can block the interaction of LAG-3 with HLA-DR (MHC-II) and activate CD8+ T cells. LAG-3 cyclic peptide inhibitor C25 can be used in the study of cancer[1].

Product Specifications

UNSPSC

12352209

Target

LAG-3

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

O=C(N[C@@H](C(C)C)C(N1[C@@H](CCC1)C(N[C@@H](CCSC)C(N[C@@H]([C@H](O)C)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H](CCCNC(N)=N)C(N[C@H]3C)=O)=O)=O)=O)=O)=O)[C@H](CSSC[C@@H](C(O)=O)NC3=O)N

Molecular Formula

C43H68N12O12S3

Molecular Weight

1041.27

References & Citations

[1]Zhai W, et al. A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses. Acta Pharm Sin B. 2020 Jun;10 (6) :1047-1060.